EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic timing limitations of postnatal darbepoetin in a valproic acid rat model of Autism Spectrum Disorder

Ömer Yusuf İpek iD, Tuğba Kirboğa, Ercan Babur, Nurcan Dursun, Cem Süer

PLOS One · 2025

DOI: 10.1371/journal.pone.0337294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ömer Yusuf İpek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Valproic Acid, Darbepoetin alfa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bilimsel Araştırma Projeleri, Erciyes Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autism spectrum disorder (ASD) arises from complex genetic and environmental factors that disrupt neural development during early brain maturation. Erythropoietin (EPO) has been studied for its neuroprotective effects and more recently for its potential to influence neurodevelopment in early postnatal ASD models. However, ASD is not typically diagnosed in humans until 2–3 years of age, a stage well beyond early postnatal development. To address this timing gap, we administered darbepoetin alfa, a long-acting EPO analogue, to valproic acid-exposed rats beginning at postnatal day 21 for five consecutive days, and assessed ASD-relevant social and cognitive behaviors. Behavioral assessments using the three-chamber test and Morris Water Maze revealed no significant improvements in ASD-relevant behaviors despite clear systemic activity, as evidenced by substantial hematocrit elevation (~70%). Our findings suggest the therapeutic window for EPO analogues may close before the post-diagnostic period, highlighting a critical translational challenge: interventions effective in early neonatal windows may not retain efficacy at clinically accessible diagnostic stages. The pronounced hematological response further precludes testing whether higher doses could compensate for delayed timing, though non-erythropoietic derivatives may circumvent this limitation in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autism Spectrum DisorderValproic AcidDarbepoetin alfaAnimalsRatsDisease Models, AnimalMaleBehavior, AnimalFemaleRats, Sprague-DawleyAnimals, NewbornErythropoietin

Substanzen

Valproic AcidDarbepoetin alfaErythropoietin

Autor:innen und Institutionen

  • Department of Physiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
  • Department of Physiology, Faculty of Medicine, Ahi Evran University, Kırşehir, Turkey.

ORCID-Profile: Ömer Yusuf İpek

Förderung

  • Bilimsel Araştırma Projeleri, Erciyes Üniversitesi

Zitieren

APA

İpek, Ö. Y., Kirboğa, T., Babur, E., Dursun, N., & Süer, C. (2025). Therapeutic timing limitations of postnatal darbepoetin in a valproic acid rat model of Autism Spectrum Disorder. PLOS One. https://doi.org/10.1371/journal.pone.0337294

Vancouver

İpek ÖY, Kirboğa T, Babur E, Dursun N, Süer C. Therapeutic timing limitations of postnatal darbepoetin in a valproic acid rat model of Autism Spectrum Disorder. PLOS One. 2025. doi:10.1371/journal.pone.0337294

BibTeX
@article{pek2025,
  author = {İpek, Ömer Yusuf and Kirboğa, Tuğba and Babur, Ercan and Dursun, Nurcan and Süer, Cem},
  title = {Therapeutic timing limitations of postnatal darbepoetin in a valproic acid rat model of Autism Spectrum Disorder},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0337294}
}
Kostenlos starten →